Classification of
Softer Q2 figures, but on track to reach the guidance Gross sales came in at € 57.8m (2% yoy), below our estimate of € 64.2m, despite a very positive AUA development reaching € 30bn end of July (vs € 28.3bn in FY24), driven by further inflows and solid market performance. The topline decline can partially be explained by delayed revenue recognition in Q2 that should be visible in higher Q3 sales. Positively, material expenses should have declined in absolute numbers and remained stable relatively to sales at 81.5% (vs 81.4% in Q1´25) resulting in net sales of € 10.7m (-2% yoy vs eNuW: € 11.9m). EBITDA stood at € 2.0m (-3% yoy), below our estimate of € 2.7m, and Q1 figures of € 2.8m, mainly driven by the softer topline development. That said, personnel expenses should have remained rather stable at € 6.0m (eNuW, 2% yoy) and other OPEX should have even declined to € 2.7m (eNuW, -10% yoy, -16% qoq vs eNuW old: € 3.2m). EBT should have come in at € 0.9m (vs € 1.4m in Q2´24 vs eNuW: € 1.6m) with D&A that should have remained stable (eNuW: € 1.2m) and a financial result that was burdened by the interest payment for the bond (eNuW: € -0.2m). In a nutshell, Q2 was not as strong as anticipated, but nothing to be worried about. Especially the ongoing strong AuA development serves as an indicator for future topline growth that should already start to materialize in Q3 . Knowing that the more profitable AuM´s are growing more dynamically, EBITDA margins should expand further. Hence, we still see the company well on track to reach its FY25 guidance. As the anticipated growth should be strongly supported by For FY25 we now expect € 268m gross sales, € 53.8m net sales and an EBITDA of € 12.6m, which is in line with the guidance of € 260-270m gross sales, € 52.5-54m net sales and an EBITDA of € 12-13.5m. Both, guidance and our estimates can be considered as conservative and with room for an update until eoy. BUY with a reduced PT of € 74.00 (old: € 78.00), based on DCF. You can download the research here: netfonds-ag-2025-09-05-update-en-27365 For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 ++++++++++ Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, |
2193432 05.09.2025 CET/CEST